Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials
Explore this paper's citation graph
Summary
It is confirmed that patients with nccRCC are underrepresented in clinical trials and highlight the need for further prospective studies exploring current and novel agents for this patient population.
- Type
- article
- Published
- 2017-03-21
- Cited by
- 42
- References
- 40
- OpenAlex
- https://openalex.org/W2601472578
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11872758
Keywords
Medicine, Renal cell carcinoma, Oncology, Clinical trial, Internal medicine
References
- Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
- Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria
- Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
- Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma
- Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.
- 2004 WHO classification of the renal tumors of the adults.
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
- The somatic genomic landscape of chromophobe renal cell carcinoma
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
- Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma
- Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.
- Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
- Sunitinib in patients with metastatic renal cell carcinoma.
- Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
- Comprehensive Molecular Characterization of Papillary Renal Cell Carcinoma
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
- Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Cited by
- The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
- Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma
- Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme
- Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database.
- Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
- Sex‐specific analysis of renal cell carcinoma histology and survival in Japan: A population‐based study 2004 to 2016
- A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
- Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
- Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
- Identification of clinical combination therapies to induce durable responses in kidney cancers
- The immunology of renal cell carcinoma
- Kidney Cancer, Version 1.2021
- Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study.
- Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
- Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma
- Associations between T cell infiltration, T cell receptor clonality, histology and recurrence in renal cell carcinoma
- A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
- Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
Related papers
- CDCA5 is a potent therapeutic target of clear cell renal cell carcinoma
- Novel model of pyroptosis-related molecular signatures for prognosis prediction of clear cell renal cell carcinoma patients
- Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma.
- Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness
- FBXL6 depletion restrains clear cell renal cell carcinoma progression
- Loss of caspase 7 expression is associated with poor prognosis in renal cell carcinoma clear cell subtype.
- FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis
- Phase II Study of Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
- The frequence of renal cell carcinoma in population of patients with kidney tumors.
- Low-expression of ASS1 in clear cell renal cell carcinoma and its clinical significance